Clevidipine (INN trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.It was approved by the United States Food and Drug Administration on August 1 2008.
This page contains content from the copyrighted Wikipedia article "Clevidipine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
